Sun.Jul 28, 2024

article thumbnail

September is Peak Asthma Month: Is Your Child Ready?

Drugs.com

SUNDAY, July 28, 2024 -- Peak asthma month is upon parents as summer draws to a close, experts warn.“September is known as Asthma Peak Month because kids have returned to school, and viruses are being passed around,” said allergist Dr. Gailen Mar.

Virus 290
article thumbnail

The Role of Patient Advocacy Groups in Generic Drug Development

Drug Patent Watch

Patient advocacy groups have become increasingly influential in the pharmaceutical industry, particularly in the development of generic drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Impact of International Trade Agreements on Drug Patents: A Systematic Review

Drug Patent Watch

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) sets minimum standards for intellectual property protection globally, including patents […] Source

article thumbnail

Which pharmaceutical companies have the most powder dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most powder dosed drugs. For a different perspective, see the most popular dosage types.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

New tentative approval for Alembic drug dabigatran etexilate mesylate

Drug Patent Watch

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.

Drugs 52